BioCentury
ARTICLE | Company News

Janssen, Locus partner on CRISPR-Cas3 bacteriophages

January 4, 2019 1:11 AM UTC

Janssen Pharmaceuticals Inc. partnered with Locus Biosciences Inc. (Morrisville, N.C.) to develop and commercialize CRISPR-Cas3-enhanced bacteriophage therapies against two bacterial pathogens to treat infections of the respiratory tract and other organ systems.

Locus will receive $20 million up front and is eligible for up to $798 million in milestones, plus royalties...